David Nichols Recommends the Following Stocks: Inamed Corp. and Penwest Pharmaceuticals.Business Editors CHICAGO--(BUSINESS WIRE)--Jan. 17, 2003 Finding a profitable investment isn't that difficult when you know where to look. But, as everyone now knows, that's easier said than done. David Nichols gives readers a shove in the right direction, with a couple of recommendations that seem to be in the right place at the right time. Read his takes on Inamed Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :IMDC IMDC Illinois Medical District (Chicago, IL) IMDC Integrated Mission Design Center (NASA) IMDC Isolated, Missing, Detained, or Captured (personnel recovery) ) and Penwest Pharmaceuticals (Nasdaq:PPCO PPCO Phillips Petroleum Company PPCO Provisioning Principal Contracting Office PPCO Penwest Pharmaceutical Company ). Click here for the full story exclusively on Zacks.com: http://featuredexpert2bw.zacks.com/ Here are the highlights from the Featured Expert column: Plain and simple, we need a resolution to this Iraqi situation. Nichols' puzzlement puz·zle·ment n. The state of being confused or baffled; perplexity. Noun 1. puzzlement - confusion resulting from failure to understand bafflement, befuddlement, bemusement, bewilderment, mystification, obfuscation over the potential outcome is exactly the same thing that tens of millions of other market participants The term market participant is used in United States constitutional law to describe a U.S. State which is acting as a producer or supplier of a marketable good or service. When a state is acting in such a role, it may permissibly discriminate against non-residents. are experiencing. Nobody knows. And basically, that has been -- and will continue to be -- the dominant market theme. As long as this uncertainty exists, it will be tough to make money on the long side. Inamed Corp. (NASDAQ:IMDC) is advancing in the very fast-growing aesthetic "lifestyle" niche. With millions of affluent middle-aged Americans and Europeans looking unhappily in the mirror, and millions more headed inevitably toward middle age over the next 20 years (to be followed by their own children), Inamed is in the right place at the right time. Inamed makes money in every product category, both in the U.S. and internationally. Total sales for the third quarter were $67 million, up 18% over last year, with earnings per share up 38%. The stock traded recently at $32; the market capitalization Market Capitalization A measure of a public company's size. Market capitalization is the total dollar value of all outstanding shares. It's calculated by multiplying the number of shares times the current market price. This term is often referred to as market cap. is a surprisingly low $703 million. Inamed has $58 million in cash, some of which it will need for upcoming product trials. It won't surprise Nichols if Inamed declares a dividend within the year. Penwest Pharmaceuticals (Nasdaq:PPCO) develops drug products based on novel drug delivery technologies. It's developed an unusual new controlled-release technology called TIMERx. TIMERx is being used in an oxymorphone extended-release (ER) tablet See digitizer tablet and tablet computer. TABLET - A query language. ["Human Factor Comparison of a Procedural and a Non-procedural Query Language", C. Welty et al, ACM Trans Database Sys 6(4):626-649 (Dec 1981)]. by Endo Pharmaceuticals Endo became Endo Pharmaceuticals Inc. as a result of a management buyout from DuPont Merck in 1997. Endo is a specialty pharmaceutical company engaged in the research, development, sale and marketing of prescription pharmaceuticals used primarily to treat and manage pain. , who makes big-name pain-management drugs including Percocet and Lidoderm. Penwest gets revenue from royalties, licensing arrangements, milestone payments, and from the purchase of formulated for·mu·late tr.v. for·mu·lat·ed, for·mu·lat·ing, for·mu·lates 1. a. To state as or reduce to a formula. b. To express in systematic terms or concepts. c. TIMERx material. Par for the course, third-quarter net loss was up slightly to $4.5 million, since research, development and clinical trials cost a bundle. Revenues were $11 million compared to last year's $9.8 million. It traded recently at $10.65. Market cap is a reasonable $163 million, and the high short interest should help to prop up the stock price. Receive even more information on the above-mentioned companies, and get several more of David Nichols' recommendations, by clicking: http://featuredexpert3bw.zacks.com/ About Zacks Featured Experts To be a successful investor you need professional advice. Experts who know what they're talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc. Recommendations from Featured Experts Highlighted in FREE Investment Newsletter The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail See Internet e-mail service. newsletter. Get your free subscription to "Profit from the Pros" at: About Zacks Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1981 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://www.freeprofitbw.zacks.com Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation solicitation In criminal law, the act of asking, inducing, or directing someone to commit a crime. The person soliciting another becomes an accomplice to the crime. The term also refers to the act of obtaining bribes, as well as to the crime of a prostitute who offers sexual to buy or sell any security. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion